The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 360:1358-1359 March 26, 2009 Number 13
NextNext

Azathioprine or Methotrexate Maintenance for ANCA-Associated Vasculitis

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Pagnoux, C.
-PubMed Citation
To the Editor: In their prospective, open-label trial, Pagnoux et al. (Dec. 25 issue)1 compared azathioprine (at a dose of 2 mg per kilogram of body weight per day) with methotrexate (at a dose of 0.3 µg per kilogram per week, progressively increased to 25 mg per week) as maintenance therapy for antineutrophil cytoplasmic antibody (ANCA)–associated vasculitides (Wegener's granulomatosis and microscopic polyangiitis). They provide evidence-based data about both the efficacy and the safety profile of these drugs. Like the authors, we were surprised by the tendency toward a better safety profile for azathioprine (a trend that did not support their . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.